Inhibitor of TGF-β activation reaction

Details Inhibitor of TGF-β activation reaction Inhibitor of TGF-β activation reaction

2008-03-07

2010-06-08

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07732401

ABSTRACT:
The present invention aims to provide a substance(s), especially a peptide(s) capable of inhibiting the TGF-β activation reaction. The present invention provides a peptide consisting of 11 to 50 amino acid residues, which comprises an amino acid sequence Gln-Ile-Leu-Ser-X1-X2-X3-X4-Ala-Ser-Pro (SEQ ID NO: 1) wherein each of X1 to X4 independently represents any given amino acid residue, and X1-X2-X3-X4 is a sequence that is not Lys-Leu-Arg-Leu (SEQ ID NO: 12) and is not cleavable by proteases.

REFERENCES:
patent: 2008/0038748 (2008-02-01), Kojima et al.
patent: 2003-252792 (2003-09-01), None
patent: 2004-121001 (2004-04-01), None
patent: 2005-239695 (2005-09-01), None
patent: 2005/023870 (2005-03-01), None
patent: 2005/039570 (2005-05-01), None
patent: WO 2007121233 (2007-10-01), None
Swann et al., “Nonspecific Protease-Catalyzed Hydrolysis/Synthesis of a Mixture of Peptides: Product Diversity and Ligand Amplification by a Molecular Trap,” Biopolymer, 1998, 40, 617-25.
Nishiya et al. “A purification method of the diagnostic enzyme Bacillus uricase using magnetic beads and non-specific protease,” Protein Expression and Purification, 2002, 25, 426-429.
Juhasez et al. “The utility of nonspecific proteases in the characterization of glycoproteins by high-resolution time-of-flight mass spectrometry,” International Journal of Mass Spectrometry and Ion Processes, 1997, 169/I 70, 217-230.
Salisbury et al. “Peptide Microarrays for the Determination of Protease Substrate Specificity,” JACS, 2002, 124,14868-70.
Rawlings, N.D., Morton, F.R., Kok, C.Y., Kong, J. & Barrett, A.J. (2008) MEROPS: the peptidase database. Nucleic Acids Res 36, D320-D325.
Peptide Cutter, http://ca.expasy.org/tools/peptidecutter/peptidecutter—enzymes.html.
Gomes et al. “Proteolytic Mapping of Human Replication Protein A: Evidence for Multiple Structural Domains and a Conformational Change upon Interaction with Single-Stranded DNA,” Biochemistry, 1996, 35, 5586-95.
Rail et al. “The Domain Structure of Human Receptor-associated Protein, Protease Sensitivity and Guanidine HCI Denaturation,” J. Biol. Chem., 1998, 273, 24152-7.
Speicher et al. “Spectrin Domains: Proteolytic Susceptibility as a Probe of Protein Structure,” J. Cell. Biochem., 1982, 18, 479-492.
Hervivo et al. “Negative selectivity and the evolution of protease cascades: the specificity of plasmin for peptide and protein substrates,” Chem. & Bio., 2000, 7, 443-452.
Lovgren et al. “Enzymatic action of human glandular kallikrein 2 (hK2) Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors,” Eur. J. Biochem. 1999, 262, 781-789.
Sugita et al. “Complete nucleotide sequence of the freshwater unicellular cyanobacteriumSynechococcus elongatusPCC 6301 chromosome: gene content and organization,” Photosynthesis Research, 2007, 93, 55-67, published online Jan. 9, 2007.
CAS 2007:936363.
MEROPS http://merops.sanger.ac.uk/, printed Jul. 17, 2009.
English Language Abstract of JP 2004-121001.
Schuppan et al. “Hepatic Fibrosis—Therapeutic Strategies”Digestion59:385-390 (1998).
Qi et al. “Blockade of type β transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat”Proc. Natl. Acad. Sci. USA96:2345-2349 (1999).
Ueno et al. “A Soluble Transforming Growth Factor β Receptor Expressed in Muscle Prevents Liver Fibrogenesis and Dysfunction in Rats”Hum. Gene. Ther. 11:33-42 (2000).
Okuno et al. “Prevention of Rat Hepatic Fibrosis by the Protease Inhibitor, Camostat Mesilate, via Reduced Generation of Active TGF-β”Gastroenterology120(7):1784-1800 (2001).
Akita et al. “Impaired Liver Regeneration in Mice by Lipopolysaccharide Via TNF-α/Kallikrein-Mediated Activation of Latent TGF-β”Gastroenterology123:352-364 (2002).
English Language Abstract of JP 2003-252792.
Schultz-Cherry et al. “Regulation of Transforming Growth Factor-β Activation by Discrete Sequences of Thrombospondin 1”J. Biol. Chem.270(13):7304-7310 (1995).
Crawford et al. “Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo”Cell93:1159-1170 (1998).
Ribeiro et al. “The Activation Sequence of Thrombospondin-1 Interacts with the Latency-associated Peptide to Regulate Activation of Latent Transforming Growth Factor-β”J. Biol. Chem. 274(19):13586-13593 (1999).
Murphy-Ullrich et al. “Activation of latent TGF-β by thrombospondin-1: mechanisms and physiology”Cytokine&Growth Factor Reviews11:59-69 (2000).
Kondo et al. “Molecular Mechanism and Regulation of Latent TGF-β Activation”Nihon Kessen Shiketu Gakkaishi(The Bulletin of the Japanese Society on Thrombosis and Hemostatis) 14(3):210-219 (2003).
Annes et al. “Making sense of latent TGFβ activation”J. Cell Sci. 116:217-224 (2003).
Greenwell et al. “An enhancement method for immunohistochemical staining of proliferating cell nuclear antigen in archival rodent tissues”Cancer Letters59:251-256 (1991).
English Language Abstract of JP 2005-239695.
Gentry et al. “The Pro Domain of Pre-Pro-Transforming Growth Factor β1 When Independently Expressed Is a Functional Binding Protein for the Mature Growth Factor”Biochemistry29(29):6851-6857 (1990).
U.S. Appl. No. 10/570,606 to Kojima et al.

Affiliated with

Also associated with

Rating

Inhibitor of TGF-β activation reaction does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitor of TGF-β activation reaction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitor of TGF-β activation reaction will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4178407